Psoriasiform lesions induced by tumour necrosis factor antagonists: A skin-deep medical conundrum

Annals of the Rheumatic Diseases

Volumn 67, Issue 8, 2008, Pages 1181-1183

  Carter, J D ^a   Gerard, H C ^b   Hudson, A P ^b,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ADULT; ARTICLE; CASE REPORT; CHLAMYDIA TRACHOMATIS; FEMALE; HUMAN; HUMAN TISSUE; KERATODERMA BLENNORRHAGICA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSORIASIS; PUNCH BIOPSY; RHEUMATOID ARTHRITIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, REACTIVE; ARTHRITIS, RHEUMATOID; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FEMALE; HUMANS; IMMUNOGLOBULIN G; KERATOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; SKIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47949126329     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.082842     Document Type: Article

References (14)

1. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006;295:2275-85.
2. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:666-76.
3. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005;52:2513-8.
4. Ritchlin C, Tausk F. A medical conundrum: onset of psoriasis in patients receiving anti-tumor necrosis factor agents. Ann Rheum Dis 2006;65:1541-4.
5. Camisa C. Handbook of psoriasis. 2nd ed. Oxford: Blackwell Publishing, 1998:21.
6. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
7. Whittum-Hudson JA, Gérard HC, Schumacher HR, Hudson AP. Pathogenesis of Chlamydia-associated arthritis. In: Bavoil P, Wyrick P, eds, Chlamydia - pathogenesis and treatments.Oxford: Blackwell Publishing, 2006:475-504.
8. Inman RD, Whittum-Hudson JA, Schumacher HR, Hudson AP. Chlamydia-associated arthritis. Curr Opin Rheumatol 2000;12:254- 62.
9. Schneider JM, Matthews JH, Graham BS. Reiter's syndrome. Cutis 2003;71:198-200.
10. Ishihara T, Aga M, Hino K, Ushio C, Taniguchi M, Iwaki K, et al. Inhibition of chlamydia trachomatis growth by human interferon-alpha: mechanisms and synergistic effect with interferon-gamma and tumor necrosis factor-alpha. Biomed Res 2005;26:179-85.
11. Inman RD, Chiu B. Early cytokine profiles in the joint define pathogen clearance and severity of arthritis in Chlamydia-induced arthritis in rats. Arthritis Rheum 2006;54:499-507.
12. Gérard HC, Wang Z, Whittum-Hudson JA, Bardin T, Schumacher HR, Hudson AP. Cytokine and chemokine mRNA produced in synovial tissue chronically infected with C trachomatis and Chlamydia pneumoniae. J Rheumatol 2002;29:1827-35.
13. Gérard HC, Branigan PJ, Schumacher HR, Hudson AP. Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression. J Rheumatol 1998;25:734-42.
14. Carter JD. Reactive arthritis: defined etiologies, emerging pathophysiology, and unresolved treatment. Infect Dis Clin North Am 2006;20:827-47.